Lung Cancer Registry

Condition(s) studied

Study summary

Lung cancer is the second most common cancer in Austria with 2.868 men and 2.009 women diagnosed in 2016. Reflecting the high mortality of this disease, 2.415 men and 1.534 women died from lung cancer. Therefore, lung cancer is the most common reason for cancer associated death in men and second most common reason in women.

This malignant disease can be divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is a paradigm for personalized medicine, with an increasing number of targetable gene alterations. Despite this growing diversity of molecular subtypes, in most patients no targetable mutation can be detected. For these patients check-point inhibitors with or without chemotherapy is the mainstay of the initial tumor therapy. Until recently, little progress has been made in the treatment of SCLC in last decades. Recently, an overall survival benefit by the addition of an immune-checkpoint inhibitor to first-line chemotherapy for advanced SCLC has been reported.

Despite the progress in the treatment of NSCLC, the performance of predictive biomarkers is weak. Therefore, the development of more precise prediction models is of great importance for the progress of personalized treatment strategies.

Eligibility

Primary outcome measure(s)

• General characteristics — 10 years
  To describe the general characteristics of advanced or metastatic stage patients in Austria (Stage III A-C and IV A-B NSCLC, limited disease (LD) and extensive disease (ED) SCLC)
• Molecular testing — 10 years
  To describe molecular testing in patients with advanced or metastatic lung cancer * number of patients with molecular testing * methods for molecular testing * number of patients with PD-L1 testing * PD-L1 % range per disease stage * PD-L1 test antibody used * number of genes tested * number of patients with at least one mutation identified * number of patients with at least one druggable target identified
• Characterize subgroups — 10 years
  To describe and characterize subgroups * Number of patients with NSCLC * Number of patients that receive immune-checkpoint inhibitors * Number of patients with targetable/druggable mutations
• Treatment duration — 10 years
  To describe duration of treatment
• Treatment frequency — 10 years
  To describe frequency of treatment
• Degree of treatment response — 10 years
  To describe degree of treatment response in %
• Treatment sequence — 10 years
  To describe sequence of use of various treatments
• Outcome OS — 10 years
  To describe patient outcome by means of overall survival (OS) in %
• Outcome PFS — 10 years
  To describe patient outcome by means of progression free survival (PFS) in %
• Toxicity of treatment — 10 years
  To describe number of patients with toxicity of treatment with a focus on immune related adverse events

Trial sites (3)

More Arbeitsgemeinschaft medikamentoese Tumortherapie trials in Austria

Other trials for the same condition